Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca R Roylance

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Genes, Chromosomes & Cancer|July 12, 2002
Loss of heterozygosity analysis: practically and conceptually flawed?Ian P M Tomlinson, Maryou B K Lambros, Rebecca R Roylance
The Journal of Pathology|December 9, 2004
Analysis of ovarian cancer cell lines using array-based comparative genomic hybridizationMaryou B K Lambros, Heike Fiegler, Angela Jones, et al.
Oncogene|November 9, 2004
Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinomaAngela M Jones, Eleanor J Douglas, Sarah Er Halford, et al.
Cancer Research|April 6, 2006
Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancersMichelle Gaasenbeek, Kimberley Howarth, Andrew J Rowan, et al.
The Journal of Pathology|November 5, 2003
MSI-low, a real phenomenon which varies in frequency among cancer typesSarah E R Halford, Elinor J Sawyer, Maryou B Lambros, et al.
Nature Genetics|February 28, 2002
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancerIan P M Tomlinson, N Afrina Alam, Andrew J Rowan, et al.
Nature|April 8, 2024
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancerJean E Abraham, Karen Pinilla, Alimu Dayimu, et al.
Nature Communications|May 13, 2025
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trialJean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Genes, Chromosomes & Cancer|July 12, 2002
Loss of heterozygosity analysis: practically and conceptually flawed?Ian P M Tomlinson, Maryou B K Lambros, Rebecca R Roylance
The Journal of Pathology|December 9, 2004
Analysis of ovarian cancer cell lines using array-based comparative genomic hybridizationMaryou B K Lambros, Heike Fiegler, Angela Jones, et al.
Oncogene|November 9, 2004
Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinomaAngela M Jones, Eleanor J Douglas, Sarah Er Halford, et al.
Cancer Research|April 6, 2006
Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancersMichelle Gaasenbeek, Kimberley Howarth, Andrew J Rowan, et al.
The Journal of Pathology|November 5, 2003
MSI-low, a real phenomenon which varies in frequency among cancer typesSarah E R Halford, Elinor J Sawyer, Maryou B Lambros, et al.
Nature Genetics|February 28, 2002
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancerIan P M Tomlinson, N Afrina Alam, Andrew J Rowan, et al.
Nature|April 8, 2024
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancerJean E Abraham, Karen Pinilla, Alimu Dayimu, et al.
Nature Communications|May 13, 2025
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trialJean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz, et al.
Pageof 1